Information Letter of the European LeukemiaNet
The Information Letter is provided as needed, usually before the annual Symposium of the European LeukemiaNet. It is a collaboration of the European Leukemia Information Center (ELIC), the Network Management Center (NMC), and the contributing authors. Topics of this online-publication medium range from basic research to clinical trials and the latest activities of the different work packages.
|
All ELN members are cordially invited to submit proposals of their field of research for prospective Information Letters to ELIC. |
|---|
Current issue of the ELN Information Letter
Information Letter no. 12, February 2016
for free download
- Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: Registry results from the PROMYSE project of the ELN
- TP53 defect: The irrepressible fortress in chronic lymphocytic leukemia?
- Chronic lymphocytic leukemia: The impact of newly accepted therapies
- Current status of interferon-based regimens ongoing worldwide for chronic myeloid leukemia patients
- Prognosis of long-term survival in patients with chronic myeloid leukemia
- MDS-prognosis according to IPSS and IPSS-R by CD34 FISH of peripheral blood cells
- MDS-RIGHT: Providing the right care to the right patient with Myelodysplastic Syndrome at the right time
- EU-Regulation: Timelines and characteristics
- Experts unite to form a new global acute myeloid leukemia network
- ASH 2015: Abstract summaries
Privious issues of the ELN Information Letter
Information Letter no. 11
for free download
- Clinical endpoints for drug treatment trials in BCR-ABL1-negative classic MPNs
- Survival and prognosis in patients with first-line imatinib under particular consideration of death due to CML
- Incidence of CML in Europe - An estimation from the EUTOS population-based registry
- Genetic elucidation of oncogene amplification in MDS and AML
- Pregnancy in patients with chronic myeloid leukemia: ELN CML Pregnancy Registry
- EUMDS Registry: Ongoing activities and developments
- DACOTA TRIAL for advanced proliferative CMML by the GFM, FISM and GMDS study groups
- MDM-portal: A portal of medical documentation forms for leukemia research
- EU-Regulation: Consequences for academic research
- ASH 2014: Abstract summaries
Information Letter no. 10
for free download
- WP11 – CYTOGENETICS: Current and future activities in Cytogenetics
- WP5 – AML: The importance of minimal residual disease (MRD) in AML
- WP14 - SCT: Role of stem cell transplantation in elderly patients with AML
- WP8 – MDS: Diagnosis and treatment of primary myelodysplastic syndromes in adults. Recommendations from the European
- LeukemiaNet
- WP4 – CML: CML immunology: an update
- WP6 – ALL: Philadelphia Positive Acute Lymphoblastic Leukemias in the elderly: a European LeukemiaNet perspective
- WP10 – DIAGNOSTICS: Projects 2013-2014
- WP8 – MDS: ABT-737 targets NRAS by inhibiting its partner BCL-2
- EUTOS: Highlights of EUTOS
- ELN FOUNDATION: News from ELN Foundation
- ASH 2013: Abstract summaries
Information Letter no. 9
for free download
- WP5 – AML: Towards an integrated, risk adapted application of allogeneic stem cell transplantation for patients with AML in first complete remission
- WP6 – ALL: Current approaches for antibody therapy in acute lymphoblastic leukemia (ALL)
- WP11 – Cytogenetics: Quality assurance in leukemia cytogenetics by web-based processing of interlaboratory tests
- WP4 – CML: European LeukemiaNet recommendations for the management and the treatment of chronic myeloid leukemia
- WP15 – Supportive care: Recommendations on the management of respiratory viral infections
- WP8 – MDS: Highlights from the MDS European LeukemiaNet WP 8
- WP10 – Diagnostics: Highlights from the field of diagnosis
- WP7 – CLL : European Research Initiative on CLL (ERIC) / ELN WP7
- WP2 – ELIC: New European regulation on clinical trials on medicinal products for human use
- EUTOS: Standardized definitions of molecular response in CML
- ASH 2012: Clinical Results from Oral Presentations Summary of Selected Abstracts
Information Letter no. 8
for free download
- WP8 – MDS: Highlights from the MDS field: European LeukemiaNet
- WP8 – MDS: TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression
- WP8 – MDS: Flow cytometry in myelodysplastic syndromes. Definitions, Clinical and Diagnostic Applications
- WP4 – CML: Euro-SKI: Europe stop tyrosine kinase trial – the rational
- WP5 – AML: The Role of Age versus Treatment Intensity in AML
- WP9 – MPN: A novel murine model of MPN, generated by NF-E2 overexpression, displays spontaneous transformation to acute leukemia
- WP6 – ALL: Recommendations of the European Working Group for Adult ALL
- WP6 – ALL: Clinical Trials Directive – planned amendment by the EU
- WP7 – CLL: European Research Initiative on CLL (ERIC)
- ELN Foundation: Two Years of ELN Foundation
- EUTOS for CML: Latest News about EUTOS
Information Letter no. 7
for free download
- WP4 – CML: To stop treatment with Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
- WP9 – CMPD: SNP-Array Based Analysis in Myeloproliferative Neoplasms
- WP11 – Cytogenetics: Whole genome sequencing
- WP4 – CML: The EUTOS for CML Registry
- WP5 – AML: Prospective comparison of different treatments with a common standard Treatment-Study by the German AML Intergroup
- WP5 – AML: EBMT/ELN study for elderly patients with AML
- WP5 – AML: TET2 Mutations in Acute Myeloid Leukemia (AML)
- WP6 – ALL: Bispecific T-cell engaging (BiTE) Antibody Blinatumomab
- WP9 – CMPD: Philadelphia-Negative Classical MPN: Critical concepts and Management Recommendations
- WP10 – Diagnostic Platform: A European consenus report on blood cell identification
- WP12 – MRD: A step in the right direction towards standardized reporting of minimal residual disease data
- WP2 – ELIC: EU-directive on good clinical practice: Impact for independent research?
- WP1 – NMC: ESF-ELN Research Networking Programms
Information Letter no. 6
for free download
- WP4 – CML: Update of ELN treatment recommendations for chronic myeloid leukemia
- EUTOS for CML: A successful collaboration
- WP5 – AML: Is there a role for immunotherapy in maintaining complete remission in acute myeloid leukemia?
- WP5 – AML: Developments in APL
- WP5 – AML: Prospective Assessment of Outcome Determinants in AML: An ELN Pilot Project
- WP14 – SCT: Main factors predicting outcome after hematopoietic stem cell transplantation
- WP11 – Cytogenetics : Polymorphisms of DNA repair and detoxification genes in chronic lymphocytic leukemia
- WP2 – ELIC: ELIC for impact assessment of EU-directive on good clinical practice
- Network News: ELN Foundation, ALL: Acute lymphoblastic leukemia, Dates/Meetings, Ongoing studies of the European LeukemiaNet in the ELTR, Recommendations and Guidelines
Information Letter No.:
Content:
5th Information Letter
September 2008
Download PDF 1,4Mb
- Project 4 CML: European Registry of chronic myelogenous leukemia patients in failure after imatinib therapy
- Project 5 AML: ChIP- chip microarrays to study the epigenome in leukemia
- Project 6 ALL: Important steps towards diagnostic standardization
- Project 7 CLL: New aspects of the updated guidelines for the diagnosis and treatment of chronic lymphocytic leukemia
- Project 13 Gene Profiling: Gene Analysis Platform (GAP) for ELN
- Network News: 1st ELN Workshop on international investigator-initiates-trials, ELTR News, A novel collaboration between academia and industry to improve treatment in CML, Dates & Meetings, Ongoing studies
4th Information Letter
October 2007
Download PDF 2Mb
- Project 4 CML: The CML Group within the European Leukemia Network agreed on a long term Collaboration with Novartis
- Project 5 AML: The AML Intergroup: A Model of Cross-Trial Networking
- Project 6 ALL: Progress in Initiation of Paneuropean Trials
- Project 7 CLL: Finding Solutions for IGHV gene mutational Analysis in CLL
- Project 11 Cytogenetics: Correlation of whole Genome tiling Resolution Array CGH with Affymetrix Array Expression Analysis in AML/MDS Patients with 11q/MLL Amplification
- Project 2 ELIC: The German Leukemia and Lymphoma Patients’ Association and the European Cancer Patient Coalition
- Project 8 MDS: Development of a frailty Index for elderly Patients with MDS and AML by applying a multimodal geriatric Assessment including Quality of life Evaluation
- Project 6 ALL:Patient Information for ALL in Eight European Languages
- Project 15 Supportive Care: New Guidelines for Preventing and Treating infectious Diseases in leukemic Patients
3rd Information Letter
January 2007
Download PDF 1,2Mb
- Project 4 CML: Recommendations for treatment of CML
- Projects 10 CLL & 13 Geneprofiling: Joint meeting at MLL, Munich
- Project 12 MRD: Development of real-time PCR
- Project 2 ELIC: European Leukemia Trial Registry
- Project 8 MDS: MDS Registry
- Project 9 CMPD: Consensus definition of resistance to Hydroxyurea in ET
- Project 11 Cytogenetics: t(16;21) (AML1-MTD16) with karyotype evolution identified in a de novo AML M1 patient
- Project 14 SCT:The unmet need for infrastructure in hematopoetic stem cell transplantation (HSCT)
2nd Information Letter
June 2006
Download PDF 4,4Mb
- Project 6 ALL: Acute lymphoblastic leukemia
- Project 7 CLL: European Research Initiative on Cll (ERIC)
- Project 8 MDS: Actual state of WP 8 (MDS)
- Project 11 Cytogenetics: Analysis of AMl/MDS Patient with 11q/Mll Gene Amplification
- Project 14 Stem Cell Therapy: Stem Cell Transplantation Activity in europe 2004
- Project 2 ELIC: Clinical Trials Registry
- Project 2 ELIC: Re-launch of the ELN-Website
1st Information Letter
August 2005
Download PDF 1,9Mb
- Project 1 NMC: News from the Network Management Center Dates, Meetings
- Project 2 ELIC: Services provided by the European Leukemia Information Center
- Project 4 CML: Actual state of WP 4 (CML)
- Project 5 AML: Experiences from a Network of AML Trials using General Up-Front Randomization and a Common Standard Treatment Arm
- Project 11 Cytogenetics: Consensus protocols for cytogenetic diagnostics in leukemia
- Project 9 CMPD: Progress report Chronic Myeloproliferative Disorders
- Project 10 Diagnostic platform: European Immunophenotyping Panels
- Project 16 New Drugs:ELTRA: European Leukemia Treatment Research Association
Editorial-Board
- Marie C. Béné
- Steven O’Brien
- Alan Burnett
- Guido Finazzi
- Christa Fonatsch
- Eliane Gluckman
- Nicola Gökbuget (Editor-in-Chief)
- David Grimwade
- Torsten Haferlach
- Jörg Hasford
- Rüdiger Hehlmann
- Dieter Hoelzer
- Per Ljungmann
- Emili Montserrat
- Dietger Niederwieser
- Susanne Saussele
- Hubert Serve
- Bengt Simonsson
- Theo J. M. de Witte